GlassScriptPhysician profile
Brian A Harris
NPI 1538272653
$383.97
in general payments reported to CMS, 2019-2025
12 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.00 · 2023: $47.34 · 2024: $26.49 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322 · Travel and Lodging: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.97 |
| Travel and Lodging | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $87.59 | 2023-2025 | Blu-U |
| Regeneron Healthcare Solutions, INC. | $62.07 | 2025 | Dupixent, Libtayo |
| Kerecis Limited | $52.90 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vyne Pharmaceuticals INC. | $22.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.99 | 2025 | |
| Dentsply Sirona INC | $21.00 | 2023 | Consumable Dentistry |
| Biofrontera INC. | $20.72 | 2025 | Ameluz |
| Mimedx Group, INC. | $20.47 | 2025 | |
| Lilly USA, LLC | $20.13 | 2025 | Taltz, Ebglyss |
| Abbvie INC. | $18.49 | 2025 | |
| Genzyme Corporation | $18.21 | 2021 | |
| Surgenex LLC | $17.61 | 2025 | Surmatrix, Ardeograft, Surgraft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.